Generation Bio Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Generation BioDie Umsatzerlöse des Unternehmens werden voraussichtlich um 15.6% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 11.5% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 24.1% pro Jahr wachsen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -19% betragen.

Wichtige Informationen

11.5%

Wachstumsrate der Gewinne

24.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	-15.6%
Zukünftige Eigenkapitalrendite	-19.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Apr 20

Generation Bio: High-Risk, Medium-To-Low-Reward

Dec 30

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Nov 11

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Jul 28

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Mar 08

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Jan 14

Generation Bio's insiders on buying spree, stock +4%

Jan 13

Generation Bio prices equity offering at $24.50

Jan 07

Generation Bio files to offer 7.5M shares

Jan 04

Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Dec 27

Generation Bio EPS misses by $0.01

Nov 10

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:GBIO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	9	-80	N/A	N/A	5
12/31/2025	7	-81	-75	-71	7
12/31/2024	18	-118	-53	-48	7
9/30/2024	19	-145	-104	-98	N/A
6/30/2024	13	-158	-110	-103	N/A
3/31/2024	10	-169	-65	-57	N/A
12/31/2023	6	-127	-60	-53	N/A
9/30/2023	3	-124	-54	-51	N/A
6/30/2023	1	-127	-50	-46	N/A
3/31/2023	N/A	-134	-101	-95	N/A
12/31/2022	N/A	-137	-111	-102	N/A
9/30/2022	N/A	-135	-111	-100	N/A
6/30/2022	N/A	-136	-114	-102	N/A
3/31/2022	N/A	-129	-112	-104	N/A
12/31/2021	N/A	-119	-98	-92	N/A
9/30/2021	N/A	-112	-94	-89	N/A
6/30/2021	N/A	-101	-91	-85	N/A
3/31/2021	N/A	-88	-80	-75	N/A
12/31/2020	N/A	-81	-76	-70	N/A
9/30/2020	N/A	-72	-68	-64	N/A
6/30/2020	N/A	-68	-66	-57	N/A
3/31/2020	N/A	-65	-62	-46	N/A
12/31/2019	N/A	-61	-60	-40	N/A
12/31/2018	0	-36	-31	-28	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GBIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: GBIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: GBIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: GBIODie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-15.6% pro Jahr).

Hohe Wachstumseinnahmen: GBIODie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-15.6% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: GBIO wird voraussichtlich in 3 Jahren unrentabel sein.

Generation Bio Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 50%

Consensus revenue estimates increase by 38%, EPS downgraded

Consensus revenue estimates increase by 29%, EPS downgraded

Consensus revenue estimates increase by 101%

Price target decreased by 16% to US$7.25

Consensus revenue estimates increase by 51%

Recent updates

New minor risk - Market cap size

Consensus revenue estimates increase by 50%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 38%, EPS downgraded

Generation Bio Co. has filed a Follow-on Equity Offering in the amount of $237 million.

Consensus revenue estimates increase by 29%, EPS downgraded

Generation Bio Co. Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms At the ASGCT 27th Annual Meeting

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Generation Bio Co., Annual General Meeting, Jun 06, 2024

Insufficient new directors

Consensus revenue estimates increase by 101%

Price target decreased by 16% to US$7.25

New major risk - Revenue and earnings growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Independent Director recently bought US$478k worth of stock

Generation Bio Co. Announces Termination of Executives, Effective on January 28, 2024

Consensus revenue estimates increase by 51%

Price target decreased by 17% to US$9.00

Generation Bio Co. Announces Demonstration of Highly Selective T Cell Transduction in Vivo with Cell-Targeted Lnp Platform

New minor risk - Market cap size

Generation Bio Co. Announces Breakthrough in Its Non-Viral Genetic Medicine Platform with Novel "Immune-Quiet" Dna

Consensus revenue estimates increase by 270%

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target decreased by 12% to US$11.42

New major risk - Share price stability

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Price target decreased by 19% to US$13.00

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$16.67

Insufficient new directors

Price target decreased to US$16.67

President exercised options and sold US$58k worth of stock

Generation Bio Co. Names Phillip Samayoa as Chief Strategy Officer

Independent Director recently bought US$127k worth of stock

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio GAAP EPS of -$0.66 misses by $0.04

Insufficient new directors

Generation Bio Co. Appoints Dannielle Appelhans as Class III Director and Member of N&G Committee

Generation Bio Co.(NasdaqGS:GBIO) dropped from Russell 2000 Growth Index

Generation Bio Co. Announces Update to its Good Manufacturing Process Manufacturing Strategy

Price target decreased to US$20.40

Insufficient new directors

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Price target decreased to US$20.40

Generation Bio Co. Appoints Antoinette Paone as Chief Operating Officer

Generation Bio: High-Risk, Medium-To-Low-Reward

Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program

Price target decreased to US$33.40

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Insufficient new directors

Chief Scientific Officer exercised options and sold US$64k worth of stock

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update

Chief Medical Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$136k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$269k worth of stock

Chief Development Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$96k worth of stock

Chief Medical Officer exercised options and sold US$351k worth of stock

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

President notifies of intention to sell stock

Generation Bio Co. Appoints Ron Cooper to its Board of Directors, Effective March 1, 2021

Co-Founder & COO Mark Angelino has left the company

Chief Development Officer exercised options and sold US$71k worth of stock

Chief Medical Officer notifies of intention to sell stock

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Generation Bio's insiders on buying spree, stock +4%